Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL28626892 | 0.96 | TSHR (0.47) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Heptane SCHEMBL652606 | 0.96 | TSHR (0.57) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL9260176 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL9253671 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL3725944 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL23068705 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL9405694 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL42593 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL2244744 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA | |
| Hexane SCHEMBL9301737 | 0.96 | TSHR (0.54) | TSHRTHRBSPHK1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110967431-A | Method for determining D-captopril and captopril related substance 8 in captopril tablets by high performance liquid chromatography | 上海普康药业有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-106645528-B | A kind of high-efficiency liquid chromatography method for detecting of ticagrelor chiral isomer content | 成都欣捷高新技术开发股份有限公司 | 2018-08-31 | — | — | CN | claimed |
| CN-106645528-A | High performance liquid chromatography detection method of content of chiral isomers of ticagrelor | 成都欣捷高新技术开发股份有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-104569262-A | Method for simultaneously determining contents of alpha-tocopherol and squalene in multiple vegetable oils | GUANGZHOU HANFANG PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | claimed |
| CN-103728395-B | Content measurement method for cholesterol in egg yolk oil | GUANGZHOU HANFANG PHARMACEUTICAL CO LTD | 2014-12-17 | — | — | CN | claimed |
| EP-1968916-B1 | Process for the separation of optical isomers of the corey lactone | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 2012-07-11 | — | — | EP | claimed |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-05-03 | — | — | US | claimed |
| CN-117630260-A | Method for detecting isomer in aryl propionic acid compound | 南京海融医药科技股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| CN-115791995-A | Detection method of esomeprazole sodium isomer for injection | 宜昌东阳光长江药业股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-112697906-B | Method for detecting chiral intermediate and enantiomer of tofacitinib | 上海博悦生物科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114073669-A | Gel containing aryl propionic acid compound | 南京海融医药科技股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-112697906-A | Method for detecting chiral intermediate and enantiomer of tofacitinib | 上海博悦生物科技有限公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-0614456-B1 | 1ALPHA,24(S)-DIHYDROXY VITAMIN D2, ITS FORMATION AND USE | BONE CARE INT INC (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5801222-A | Isolation and structure of the human cancer cell growth inhibitory cyclic octapeptides phakellistatin 10 and 11 | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1998-09-01 | — | — | US | disclosed |
| US-5426194-A | Isolation and structure of Halistatin 1 | ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0614456-A4 | 1-g(a),24(S)-DIHYDROXY VITAMIN D 2?, ITS FORMATION AND USE. | LUNAR CORP (US) | 1995-01-04 | — | — | EP | disclosed |
| EP-0614456-A1 | 1$g(a),24(S)-DIHYDROXY VITAMIN D 2?, ITS FORMATION AND USE | BONE CARE INTERNATIONAL, INC. (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0608108-A1 | Isolation and structure of halistatin 1, and its use as an anti-tumor agent | ARIZONA BOARD OF REGENTS (US) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994005630-A1 | 1α,24(S)-DIHYDROXY VITAMIN D2, ITS FORMATION AND USE | LUNAR CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | SHH, GLI1, SMO | TSHR 1341/4885THRB 484/4885SPHK1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.